Piramal Pharma
Latest, :
Latest moves
Our read of each move first, where we have one; what the report said is marked Reported.
Background
From 6 stories, the newest dated 13 Aug 2026. Summary written 3 Oct 2026.
Piramal Pharma is a pharmaceutical company that reports three businesses: CDMO, complex hospital generics and consumer healthcare. [1] source: The Hindu BusinessLine
Show 3 more paragraphs and 6 sources
It has 17 global development and manufacturing facilities and a distribution network in over 100 countries. [2] source: The Hindu BusinessLine Its consumer healthcare arm, Piramal Consumer Healthcare, sells brands including the Little's diaper brand and the newly launched i-choose. [2] source: The Hindu BusinessLine[3] source: CNBC-TV18[4] source: YourStory
For Q1 FY27, the quarter ended June 30, 2026, Piramal Pharma reported revenue of ₹2,270 crore, up 17%, and a net loss of ₹69 crore versus ₹82 crore a year earlier. [1] source: The Hindu BusinessLine[2] source: The Hindu BusinessLine CDMO revenue was ₹1,187 crore, up 19%. Complex hospital generics revenue was ₹743 crore, up 17%, and consumer healthcare revenue was ₹347 crore, up 15%. [1] source: The Hindu BusinessLine CNBC-TV18 reported that Consumer Healthcare Power Brands grew 23% year-on-year and made up 53% of Consumer Healthcare sales, while e-commerce sales rose 40%. [5] source: CNBC-TV18[3] source: CNBC-TV18 The company launched i-choose for women's intimate care. [3] source: CNBC-TV18 CNBC-TV18 also reported in August 2026 that a block sale of around 6% equity, worth approximately ₹1,750 crore, was likely. [5] source: CNBC-TV18
Business Standard reported in July 2026 that Piramal Pharma favours greenfield and organic investment over acquisitions. [6] source: Business Standard Swara Baby Products, a contract diaper maker that filed for an IPO, supplies Piramal's Little's brand. [4] source: YourStory
Sources
Questions about Piramal Pharma
How fast is Piramal Pharma growing in India?
Piramal Pharma reported Q1 FY27 revenue of ₹2,270 crore, up 17%, with consumer healthcare revenue up 15% to ₹347 crore and CDMO revenue up 19% to ₹1,187 crore. Its net loss narrowed to ₹69 crore from ₹82 crore a year earlier. [1] source: The Hindu BusinessLine
What is Piramal Pharma's current strategy in India?
In July 2026 Piramal Pharma launched i-choose for women's intimate care and said consumer healthcare growth was led by Power Brands, e-commerce and wider distribution. Business Standard reported in July 2026 that it favours greenfield and organic investment over acquisitions. [6] source: Business Standard[3] source: CNBC-TV18
Stories that mention Piramal Pharma
3 stories
Piramal Pharma is named in these stories but is not their subject.